Skip to main content

Animations

MJFF Publications

2331 - 2340 of 6258 Results
Title
Year
  • Year
  • 2022
  • 2021
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • Summary Details
    OPEN
    Title: A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.nbd.2022.105612
    Citation Count: 5
  • Summary Details
    OPEN
    Title: BDNF rs6265 Genotype Influences Outcomes of Pharmacotherapy and Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease
    Journal Name: Neuromodulation: Technology at the Neural Interface
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: other-oa
    DOI - Digital Object Identifier: 10.1111/ner.13504
    Citation Count: 9
  • Summary Details
    OPEN
    Title: Cytosolic sequestration of spatacsin by Protein Kinase A and 14-3-3 proteins
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.nbd.2022.105858
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Spontaneous changes in brain striatal dopamine synthesis and storage dynamics ex vivo reveal end-product feedback-inhibition of tyrosine hydroxylase
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2022.109058
    Citation Count: 8
  • Summary Details
    OPEN
    Title: Anxiety in Parkinson's disease: A resting-state high density EEG study
    Journal Name: Neurophysiologie Clinique
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: other-oa
    DOI - Digital Object Identifier: 10.1016/j.neucli.2022.01.001
    Citation Count: 17
  • Summary Details
    OPEN
    Title: Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2022.109213
    Citation Count: 8
  • Summary Details
    OPEN
    Title: Special Issue on new therapeutic approaches to Parkinson disease
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: other-oa
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2022.108998
    Citation Count: 4
  • Summary Details
    OPEN
    Title: Preserved motor memory in Parkinson's disease
    Journal Name: Neuropsychologia
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropsychologia.2022.108161
    Citation Count: 13
  • Summary Details
    OPEN
    Title: Necessity and feasibility of remote tele-programming of deep brain stimulation systems in Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.01.017
    Citation Count: 25
  • Summary Details
    OPEN
    Title: Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.01.022
    Citation Count: 18
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.